[ad_1]
Some vials from which the serum was administered did not have the same concentration of vaccine as others, so some volunteers received lower doses. Approximately 2,741 volunteers received a first dose at half strength, while the second dose was full.
Surprisingly, it was found that those with a lower dose were better protected by the vaccine, that is, with an efficiency of 90% compared to a 62% efficiency of volunteers with high doses. This means a combined efficiency of 70% of the vaccine. 8,895 volunteers were vaccinated with serum at the established concentration.
The first results of clinical trials in volunteers in the UK and Brazil were announced on Monday, and the vaccine is estimated to average 90%. The company did not mention the manufacturing errors that produced this data, although it did say that some of the volunteers received the first half of the dose.
Another factor that could have an impact on these preliminary results is age: people in the lowest dose group volunteer up to age 55. This factor may have contributed to greater efficiency given the stronger immune response of younger people, and not necessarily size itself, writes CBC Canada.
The efficacy of the vaccine is tested with various concentrations of serum to achieve optimal doses.
If you like this article, we hope you will join the community of readers on our Facebook page, with a Like below:
[ad_2]